The Food and Drug Administration (FDA) has approved Ofev (nintedanib; Boehringer Ingelheim) capsules as the first FDA-approved treatment to slow the rate of decline in pulmonary function in patients with systemic sclerosis-associated interstitial lung disease (SSc-ILD).
Researchers identified predictive factors associated with mortality and worsening of organ function in diffuse systemic sclerosis.
Disease improvement parallels skin improvement in early dcSSc — this is important for prognosis, and reflects the value of mRSS as an outcome measure in trials.
Researchers assessed the safety and efficacy of abatacept in patients with diffuse cutaneous systemic sclerosis (dcSSc).
Researchers sought to determine the benefits of using a prognostic equation and risk score calculator to predict survival in systemic sclerosis-associated PAH.
Red cell distribution width may help detect early incident PH in patients who are at high risk for PH development.
In patients with diffuse cutaneous systemic sclerosis, developing progressive skin fibrosis within 1 year is associated with a decline in lung function and worse survival.
Rituximab treatment improved skin fibrosis in a cohort of patients with SSc, but no significant change was observed in lung fibrosis.
Patients with systemic sclerosis-associated pulmonary arterial hypertension who were given combination sequential therapy had improved survival rates compared with patients receiving upfront combination or monotherapy.
Investigators examined the prevalence, characteristics, treatment, and outcomes for patients with pulmonary hypertension in a systemic-sclerosis-associated interstitial lung disease cohort.
